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Abstract
Lyme disease is the most prevalent arthropod borne disease in the US and it is caused by the bacterial spirochete Borrelia
burgdorferi (Bb), which is acquired through the bite of an infected Ixodes tick. Vaccine development efforts focused on the
von Willebrand factor A domain of the borrelial protein BB0172 from which four peptides (A, B, C and D) were synthesized
and conjugated to Keyhole Limpet Hemocyanin, formulated in Titer MaxH adjuvant and used to immunize C3H/HeN mice
subcutaneously at days 0, 14 and 21. Sera were collected to evaluate antibody responses and some mice were sacrificed for
histopathology to evaluate vaccine safety. Twenty-eight days post-priming, protection was evaluated by needle inoculation
of half the mice in each group with 103 Bb/mouse, whereas the rest were challenged with 105Bb/mouse. Eight weeks post-
priming, another four groups of similarly immunized mice were challenged using infected ticks. In both experiments,
twenty-one days post-challenge, the mice were sacrificed to determine antibody responses, bacterial burdens and conduct
histopathology. Results showed that only mice immunized with peptide B were protected against challenge with Bb. In
addition, compared to the other the treatment groups, peptide B-immunized mice showed very limited inflammation in the
heart and joint tissues. Peptide B-specific antibody titers peaked at 8 weeks post-priming and surprisingly, the anti-peptide
B antibodies did not cross-react with Bb lysates. These findings strongly suggest that peptide B is a promising candidate for
the development of a new DIVA vaccine (Differentiate between Infected and Vaccinated Animals) for protection against
Lyme disease.
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Introduction
Lyme disease (LD) is the most prevalent arthropod-borne
infection in the United States with 30,831 cases of LD reported to
the Centers for Disease Control and Prevention (CDC) in 2012. A
significant increase in the number of reported cases has been
observed in the past few years, classifying LD as a re-emerging
infection. Borrelia burgdorferi, the causative agent of Lyme disease, is
transmitted to humans through the bite of infected Ixodes ticks [1-
4]. This pathogen is maintained in nature through a very complex
enzootic cycle in which small mammals and birds serve as
reservoirs [5–7]. This pathogen is accidentally transmitted to
humans and companion animals where it causes disease. The
ability of this spirochetal pathogen to colonize mammals is
dependent on its ability to rapidly alter gene expression in response
to highly disparate environmental signals following transmission
from infected ticks [8–13]. Consequently, a lot of interest has been
devoted to the study of proteins differentially expressed in the tick
and the mammalian host as a way to identify potential targets for
vaccine development. One of the first targets identified using this
approach was the borrelial outer surface protein A (OspA) which
was the target in the only licensed human Lyme vaccine,
LYMErix (SmithKline Beecham) [14]. In the arthropod tick, the
OspA protein is expressed by B. burgdorferi, adhering to the tick
receptor for OspA (TROSPA) located in the tick mid-gut [15].
Upon tick feeding, OspA is down regulated allowing the bacteria
to migrate from the tick mid-gut into the salivary glands and from
there into the mammalian host [15–17]. Taking this into account,
the OspA-based vaccine induced high antibody levels in labora-
tory animals as well as in humans and consequently conferred
protection by blocking the transmission of B. burgdorferi from the
tick to the mammalian host [18–21]. Despite the fact that this
vaccine showed good protection in phase III human clinical trials,
the company voluntarily discontinued the distribution of this
vaccine [14,22–24]. This was due to a number of reasons
including a significant reduction in the vaccine demand, the
appearance of adverse reaction to the vaccine, the complicated
immunization protocol with periodic boosts to maintain high
antibody titers and age limitations [14,23,25,26]. This vaccine
formulation has been used to develop vaccines administered to
wild life (small rodents in particular) to lower B. burgdorferi burden
in the mammalian reservoirs and the tick vectors, thus reducing
the risk for human infection [27–31]. In addition, the OspA-based
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vaccine has been used in veterinary medicine for some time
(NobivacH Lyme from Merk Animal Health; LymeVaxH formu-
lated by Fort Dodge and RecombitekH Lyme y Merial) to prevent
Lyme disease in dogs [32–37]. Unfortunately there is no Lyme
vaccine currently available for use in humans and horses.
Other differentially expressed proteins such as BBA52, OspC,
BBK32 and DbpA, have been evaluated as potential vaccine
targets [38–43]. However, none of these have been tested in
human or veterinary clinical trials. Nevertheless, these target
proteins are not optimal vaccines for differentiating infected from
vaccinated animals (DIVA vaccines) since both immunized and
infected animals respond to these antigens [44–47].
In our study, we have selected the chromosomally encoded
membrane-associated protein BB0172 of B. burgdorferi to develop a
DIVA vaccine. We have previously shown that BB0172 [48]
inserts into the Borrelia outer membrane and through its von
Willebrand Factor A domain (vWFA) binds to the human integrin
a3b1. BB0172 is expressed only when shifting B. burgdorferi cultures
growing at room temperature with a pH of 7.6 (unfed tick
conditions) to 37uC at a pH of 6.8 (fed tick conditions). In addition,
BB0172 is not expressed in cultures adapted to either of the
conditions and furthermore is not recognized by serum from
infected animals nor animals immunized with the full length
protein [48]. Thus, a conserved domain in the vWFA-domain of
BB0172 could be an excellent candidate for developing a DIVA
vaccine due to the highly conserved nature of BB0172 among B.
burgdorferi sensu lato complex genospecies which cause LD in
Europe and the US [48]. In this study, we designed a series of
short peptides from the vWFA domain of BB0172 and conjugated
them to KLH as potential vaccine candidates. We immunized
C3H/HeN mice with each one of the peptides following
conventional immunization protocol. Our first goal was to identify
the most antigenic peptide, therefore, safety of each one of the
peptides was evaluated as well as the protective response they
induced in the murine model of Lyme disease. Our second goal
was to determine the potential of these peptides to protect against
Lyme disease in the murine model, using the tick challenge as the
natural way of disease transmission, and elucidate the role of
antibodies and T-cells in protection against Lyme disease.
Results
Identification of potential vaccine targets from the
BB0172 antigen
The B. burgdorferi chromosomally encoded BB0172 protein has
been shown by our laboratory to be a membrane protein
containing a VWFA domain exposed to the extracellular milieu
[48]. In our efforts to obtain specific antibodies against this protein
we observed that BALB/c mice or C3H/HeN mice could not
raise specific antibodies to the full-length BB0172 protein (Esteve-
Gassent, personal observation). After analyzing the amino acid
sequence of the vWFA-domain in BB0172, peptides A, B, C and D
with B-epitope qualities were designed and conjugated to KLH.
Following immunization of groups of mice at days 0, 14 and 21
(Fig. 1), immune protection was tested by challenging the mice 28
days post-priming by needle inoculation of some mice with the low
dose of (106ID50) and some mice with the high dose of
(10006ID50) borrelial cells/mouse. Twenty-one days post-infec-
tion, the mice were euthanized and blood and tissues were
collected to evaluate antibody responses, bacterial load and
histopathology. B. burgdorferi was recovered from tissues (skin,
spleen, inguinal lymph node, bladder, heart and joint) from all
treatment groups except from tissues collected from mice
immunized with pepB and challenged with 106 ID50 (Table 1).
Evaluation of bacterial burden in the tissues from pepB vaccinees
by q-PCR revealed low to undetectable infection levels (data not
shown).
Vaccine or B. burgdorferi-induced inflammation in joints and
heart was evaluated by histological analysis of these tissues
collected 4 weeks post-priming and 4 weeks post-infection,
respectively (Fig. 2). PepB-vaccinees developed a minimal inflam-
mation in the tibiotarsal joint similar to the background
inflammation observed in the control non-immunized group
(Fig. 2A). Peptides C and D vaccinated mice had moderate to
severe inflammation in the tibiotarsal joint after immunization
(Fig. 2A). Severe inflammation was observed in mice challenged
with 1000 6 ID50 with mice immunized with pepD having the
most severe tibiotarsal joint inflammation among the groups
tested. Histological evaluation of the heart revealed that pepB
vaccinees had no signs of inflammation after immunization and
after low dose challenge (Fig. 2B). PepD treatment induced the
highest inflammation in the heart as was observed in the joints.
Evaluation of antibody responses showed that peptide specific
IgG and IgM were relatively low in all groups regardless of the
treatment received, with slight increase in antibody levels after
immunization with peptides C and D (Fig. 3A and C). In addition,
the presence of B. burgdorferi specific antibodies was very low in all
groups after the immunization schedule was completed. Never-
theless, B. burgdorferi specific antibody titers (Fig. 3B and D) were
significantly amplified in all groups after challenge infection,
except for the IgG levels in the pepB vaccines challenged with the
low borrelial dose. Moreover, serum cross-reactivity in between
peptides was not observed (data not shown).
Since pepB induced the best protection, immunization and
needle challenge was repeated two more times and similar results
were observed with no recovery of bacteria from tissues of mice
challenged with 103 Borrelia/mouse. Consequently, pepB and
pepD (which showed no protection) were selected for the
subsequent studies using tick infection to evaluate protection
(Table 1).
Figure 1. Schematic representation of the target identification
phase. C3H/HeN mice were immunized with peptides derived from the
VWFA domain of BB0172 (A, B, C and D) conjugated to KLH and
administered at 50 mg/mouse with equal volume of TiterMaxH Gold
(Sigma-Aldrich) at days 0, 14, and 21. Four weeks post-priming, 4 mice
per treatment were sampled to evaluate vaccine safety and antibody
levels to each one of the peptides used. The other eight mice were
infected with either 103 (n = 4) or 105 (n = 4) spirochetes/mouse. Four
weeks post-challenge, mice were euthanized and blood collected to
determine antibody levels. Tissues were sampled to determine bacterial
burden by growth and qPCR as well as to determine any pathology by
histology.
doi:10.1371/journal.pone.0088245.g001
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Efficacy of pepB vaccine
BB0172 Peptide B – specific antibody titers peak 8-
weeks post-priming. Mice were immunized with pepB as
described above (Fig. 4A) and blood samples for serum were
collected at the time of priming as well as 4, 8, and 12-weeks post-
priming. PepB-specific IgG antibodies peaked at 8-weeks
post-priming and decreased to levels closer to basal at 12-weeks
post-priming (Fig. 5A). The negative control mice immunized with
peptide D had a small IgG antibody peak 4-weeks post-priming
(Fig. 5B) and this outcome was similar to the result observed in the
previous screening experiment (Fig. 3C). In addition, none of the
serum samples from immunized mice reacted with B. burgdorferi
whole cell lysates. Twelve weeks post-priming, the antibody levels
had reduced to basal levels and mice were challenged by applying
5 B. burgdorferi infected ticks per mouse. Four weeks post-challenge,
all the mice were euthanized and blood samples were collected.
PepB-immunized mice had the highest peptide-specific IgG
antibody levels as well as the anti-B. burgdorferi IgG levels (Fig.
5C). Notice that the antibody titers were also significantly higher in
the pepB-immunized group starting at 4-weeks post-priming with
maximum titers of 102,400 observed at 8-weeks post-priming (Fig.
5A). Four weeks post-tick challenge, pepB-immunized mice
showed peptide-specific IgG titers of 6,800 significantly higher
than those observed in naı¨ve infected mice and pepD-immunized
mice (Fig. 5C). Similar results were observed when Bb-specific IgG
titers were evaluated. The pepB vaccinees had IgG antibody titers
of 4,266 post-challenge, which was significantly higher than the
titers observed in the naı¨ve infected mice and the pepD vaccinees
post-challenge mice (925 and 1,925 respectively). In addition, IgM
antibody levels remained very low throughout this experiment
(data not shown) as observed in the previous study (Fig. 3 A and B).
PepD-specific IgM antibodies increased slightly after tick challenge
(Fig. 5D), whereas pepB-specific IgM antibodies remained at basal
level similar to the results observed in the earlier study (Fig. 3 A
and B). Protective IgG antibody levels specific for pepB started
peaking at 4-weeks post priming, reaching maximum levels at 8-
weeks post-priming.
In addition, we measured the levels of IgG1 and IgG2a in the
pepB-immunized group at 4, 8, and 12-weeks post-priming as well
as at 4-weeks post-tick challenge (16 weeks). As observed in Fig.
5E, IgG1 titers were significantly higher than IgG2a with a peak at
12 weeks post-priming (307,200 and 78,400 respectively). Four
weeks post-challenge, IgG1 titers (23,200) remained similar to
those observed at 12-weeks post-priming (38,400) and were
significantly higher than levels measured for IgG2a at the same
time points (850, 12-weeks post-priming and 1,250 post-challenge).
This observation suggests that the immune response after
immunization and tick infection skewed towards Th2.
BB0172 Peptide B partially protects against Lyme
disease after tick challenge. After tracking antibody responses
in the mice immunized with pepB, the mice were challenged to
determine whether or not the high antibody levels could protect
mice against Lyme disease. At 12-weeks post-priming, mice were
housed individually in wire bottom cages and challenged by
applying 5 infected I. scapularis nymphs with an average of 100 B.
burgdorferi cells per nymph. The mice were euthanized 4 weeks after
ticks were applied. Analysis of skin, spleen, inguinal lymph node,
bladder, heart and tibiotarsal joint tissues showed that pepB-
immunized group had a significantly lower percent of positive
cultures, compared with control and pepD-treated mice (Fig. 6E).
Importantly, the outcome from this challenge study using the tick
infection model, a 50% vaccine efficacy was achieved. In addition,
the bladders of the pepB-immunized mice had less bacterial load
when compared with the control and pepD-immunized groups
(Fig. 6E). Furthermore, the bacterial burden in skin and spleens of
mice immunized with pepB were significantly lower compared
with the control group (Fig. 6 A and B). Lymph nodes and joints
had very low bacterial burden in both immunized groups
regardless of the peptide used (Fig. 6 C and D). Overall, the
pepB-immunized mice had the lowest bacterial burden following
challenge using infected ticks suggesting that this is a good
candidate for the development of a Lyme disease vaccine of use in
veterinary medicine.
Table 1. Peptide B protects after needle inoculation of 106ID50 in the murine model of Lyme disease.
No. of tissues positive/No. of tissues tested
Strain and dose Skin Spleen Lymph node Bladder Heart Joint All sites
No. animals infected/ No.
animals tested
Control
103 spirochetes/mouse 4/4 4/4 4/4 4/4 4/4 4/4 24/24 4/4
PepA
103 spirochetes/mouse 4/4 4/4 4/4 4/4 4/4 4/4 24/24 4/4
105 spirochetes/mouse 4/4 4/4 4/4 4/4 4/4 4/4 24/24 4/4
PepB
103 spirochetes/mouse 0/4 0/4 0/4 0/4 0/4 0/4 0/24 0/4***
105 spirochetes/mouse 4/4 4/4 4/4 4/4 4/4 4/4 24/24 4/4
PepC
103 spirochetes/mouse 4/4 4/4 4/4 4/4 4/4 4/4 24/24 4/4
105 spirochetes/mouse 4/4 4/4 4/4 4/4 4/4 4/4 24/24 4/4
PepD
103 spirochetes/mouse 4/4 4/4 4/4 4/4 4/4 4/4 24/24 4/4
105 spirochetes/mouse 4/4 4/4 4/4 4/4 4/4 4/4 24/24 4/4
***Denotes statistically significant differences (P value , 0.001) when compared with the control group.
doi:10.1371/journal.pone.0088245.t001
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Figure 2. Representative histological images of the average level of inflammation observed in each treatment group (control,
pepA, pepB, pepC, and pepD) after immunization and/or infection with the low (103 spirochetes/mouse) or high (105 spirochetes/
mouse) doses in the tibiotarsal joint (A) and the heart (B). Tissues were histologically evaluated at four weeks post priming, as well as four
weeks post needle inoculation. Average scores for areas of inflammation were classified as 0 = none; 1 = minimal; 2 = mild; 3 = moderate; 4 = severe.
Peptide B induces minimal inflammation in hearts and tibiotarsal joints after administration in the mouse model for Lyme disease. Of all the peptides
evaluated after immunization, only peptide B showed inflammation comparable to the negative control group in both heart and joints. Similar results
were observed after infection with low doses of B. burgdorferi. Images were captured using an Olympus BX41 microscope at 200X magnification.
Average 6 SD are presented in the graphs.
doi:10.1371/journal.pone.0088245.g002
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Peptide B-specific antibodies are responsible for
protection against Lyme disease. To determine whether
the protection observed in the pepB-immunized mice was due to
the high antibody titers or the cellular immune response (Fig. 4B),
donor mice were immunized with pepB, pepD, or adjuvant only
(control). When the peptide-specific antibody titers peaked at
eight-weeks post-priming (Fig. 7A, peptide B: 100,000; peptide D:
300; control: 50) serum and splenocytes from each donor group
were transferred to recipient mice, and then challenged 48 hours
after transfer. PepB-specific antibodies protected mice challenged
with low doses of B. burgdorferi B31 (106ID50) while no protection
was observed in the other groups (Fig. 7B). In addition, splenocytes
from pepB-immunized mice conferred partial protection, which
suggests a protective role of splenocytes (Fig. 7C). Analysis of
bacterial burden in different tissues of the recipient mice showed
that animals that received anti-pepB specific antibodies had very
low bacterial numbers in tissues, especially skin and spleen,
compared to the control group or the anti-peptide D treated group
(Fig. 7 D-G). The mice that received splenocytes had higher
bacterial burden than those that received antiserum. Moreover,
mice that received splenocytes from pepB vaccinees had the lowest
bacterial burden in lymph nodes and joints, compared to those
that received splenocytes from the control and pepD-immunized
mice (Fig. 7 F and G). No difference in bacterial burden was
observed between treatments in the skins and spleens. These
results suggest the relevance of specific antibodies to block
colonization.
BB0172 peptide derived antigens are safe when
injected subcutaneously in C3H/HeN mice. The safety
and tolerability of pepB immunogen was evaluated in C3H/HeN
Figure 3. Low IgM and IgG antibodies were detected 4-weeks post priming in all groups. Antibody levels were evaluated 4-weeks post-
priming as well as 4-weeks post needle infection. (A) Peptide-specific IgM antibodies. (B) B. burgdorferi-specific IgM antibodies. (C) Peptide-specific
IgG antibodies. (D) B. burgdorferi-specific IgG antibodies. * Denotes statistically significant differences (* P value ,0.05; ** P value , 0.01; *** P value
, 0.001) when compared with the control group.
doi:10.1371/journal.pone.0088245.g003
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mice by histological evaluation of tissues at 4, 8, and 12 weeks
post-inoculation. Most significant inflammation was mainly
observed after infection with high bacterial doses, regardless of
the vaccine candidate used (Fig. 2). Only minimal myocarditis and
synovitis were observed in mice after immunization with pepB, as
described above. Furthermore, no histological changes or areas of
inflammation were observed in additional tissues evaluated at 8
and 12 weeks post-priming (skin, heart, tibiotarsal joint, liver and
kidney, data not shown). Consequently, in this animal model, the
BB0172 pepB antigen was shown to be particularly safe. Further
studies in other animal models need to be done in order to confirm
the safety of this vaccine candidate.
T-cell response. PepB-specific T-cell responses in mice
immunized with the KLH-pepB conjugate or the control KLH-
peptide D conjugate were tested by proliferation assays using cells
isolated from lymph nodes or spleens. At 8 weeks post-priming,
significant pepB-specific T-cell responses and pepD-specific T-cell
responses were detected in the cells isolated from the lymph nodes
draining the immunization sites but not in splenocytes (Fig. 8A).
This outcome was rather unusual given that primed antigen-
specific T-cells were also expected to be detected in the spleen.
However, at 12 weeks post-priming, no pepB-, pepD-, nor B.
burgdorferi B31 A3-specific T-cell responses were detected in the
lymph nodes (Fig. 8B) or splenocytes (Fig. 8C). The cells from
these tissues responded well to conA mitogen suggesting that the
cells were healthy (Fig. 8 B and C).
Discussion
Currently there is no commercial LD vaccine available in the
market to protect humans, and hence we primarily rely on other
preventive measures to control the incidence of this disease,
particularly in endemic areas. A number of vaccine candidates
have been studied and tested in the mouse model for Lyme disease
as well as in wildlife [27–31] in an effort to control the spread of
this disease. Most of the approaches used in the last few years are
based on the outer-membrane lipoproteins OspA and OspC [32–
37], together with a few novel antigens such as BBA52 [38,39].
Figure 4. Summary of the study design. (A) Schematic representation of the efficacy study. C3H/HeN mice were immunized with peptide B or D
derived from the VWFA domain of BB0172 conjugated to KLH and administered at 50 mg/mouse with equal volume of TiterMaxH Gold (Sigma-
Aldrich) at days 0, 14 and 21. Eight weeks post-priming, a subgroup of mice (4/treatment) were sampled to determine antibody levels and
pathological side effects. Twelve weeks post-priming a second subgroup of mice (4/treatment) were euthanized and sampled for antibody levels in
blood, T-cell activity (from draining lymph nodes and spleens) and tissue damage. At the same time, a final group of 4 mice/treatment was infected
by tick challenge, utilizing 8 infected Ixodes scapulars nymphs/mouse (containing around 150 Borrelia/nymph). Sixteen weeks post-priming mice were
euthanized and protection evaluated by determining bacterial recovery from tissues as well as bacterial burden, tissue damage and antibody levels in
blood. (B) Schematic representation of the passive transfer experiment conducted during phase II. Donor C3H/HeN were immunized with peptide B
or D administered at days 0, 14, and 21. Eight weeks post-priming, donor mice were euthanized and blood and spleens were collected. Serum and
splenocytes were isolated and passively transferred to recipient mice. Two-days after transfer mice were infected with either a low (103 spriochetes/
mouse) or a high (105 spirochetes/mouse) dose of B. burgdorferi B31 by subcutaneous inoculation. Four weeks post-challenge mice were euthanized
and protection was evaluated.
doi:10.1371/journal.pone.0088245.g004
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Dogs and horses have been identified as sentinels for Lyme
disease across the US [56–58]. Under this scenario, and since
Lyme disease affects both humans and companion animals, the
development of a DIVA vaccine (differentiating infected from
vaccinated animals) will be of great value in the control of Lyme
disease utilizing a global health approach [59–62]. The DIVA
vaccine strategy will not only improve our diagnostic capabilities,
but also helps us in the prevention of Lyme disease in companion
animals and in the reduction of reservoir competence. Therefore,
a new Lyme DIVA vaccine can significantly impact the prevention
of LD in humans and animals.
Our previous studies have identified BB0172, a chromosomally
encoded borrelial protein anchored to the outer membrane
through two hydrophobic domains [48]. In addition, BB0172 is
conditionally expressed and has been shown to bind to integrins
a3b1 in vitro as it is relatively conserved among Borrelia species [48].
Therefore, we hypothesized that this protein could be an effective
vaccine candidate due to both its function as an adhesin and the
fact that sera from naturally infected animals did not react to this
protein in ELISA and immunoblot assays [48]. Consequently, we
developed a number of short peptides conjugated to a hapten
(KLH). Our results showed that mice immunized with the pepB
formulation were protected against infection with pathogenic B.
burgdorferi administered by injection at low infectious doses. These
results supported the hypothesis that pepB could be a strong
vaccine candidate to prevent Lyme disease. In addition, no
inflammation was observed in hearts and joints from animals
receiving this vaccine formulation, even after infecting with low
Figure 5. Peptide B-specific antibodies picked 8-weeks post immunization and were significantly stimulated 4 weeks post-tick
infection. (A) IgG antibodies specific to Peptide B (open bars) and B. burgdorferi (grey bars) at weeks 0, 4, 8, and 12 post-priming. (B) IgG antibodies
specific to Peptide D (open bars) and B. burgdorferi (grey bars) at weeks 0, 4, 8, and 12 post-priming. IgG (C) and IgM (D) antibody levels specific to
each of the BB0172 peptide (open bars) and B. burgdorferi (gray bars) in control and animals immunized with either Peptide B or D 4-weeks post tick
infection. (E) IgG1 and IgG2b antibody levels after 4, 8, 12 and 16 weeks post-priming with pepB. Titer represented in parenthesis. * Denotes
statistically significant differences (* P value ,0.05; ** P value , 0.01; *** P value , 0.001) when compared with the control group.
doi:10.1371/journal.pone.0088245.g005
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Figure 6. Peptide B induces partial protection in mice infected by using the tick model. Bacterial burden in tissues was significantly lower
in animal immunized with Peptide B especially in skin (A) and spleen (B). Lymph nodes (C) and joints (D) show lower bacterial burden in both
Peptide B and D immunized mice. Nevertheless, the bacterial recovery in cultures (E) was significantly reduced in mice receiving the Peptide B
formulation compared with Peptide D or the control group. * Denotes statistically significant differences (* P value ,0.05; ** P value , 0.01) when
compared with the control group.
doi:10.1371/journal.pone.0088245.g006
New DIVA Lyme Vaccine Candidate
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doses of B. burgdorferi. Very low peptide-specific antibody titers
were observed in this first screening experiment. After infection,
only high B. burgdorferi specific antibody titers were generated in all
groups except in animals immunized with pepB and infected with
low borrelial doses.
Following low dose B. burgdorferi challenge, pepB conferred the
highest vaccine efficacy (100%) compared with the other peptides
tested, and therefore was selected as a potential DIVA vaccine
antigen. We also selected pepD as a negative control as it is a
peptide from the same protein but it did not confer protection. In
our studies, the antibody titers for pepB consistently increased
during the weeks following the immunization schedule, peaking at
8-weeks post-priming. We evaluated the protection acquired after
vaccination by exposing the mice to B. burgdorferi through the
natural route of infection. Using infected I. scapularis ticks directly
after the antibody levels returned to basal level, we consistently
observed that pepB-immunized mice were significantly protected
against infection.
Passive transfer of sera from pepB-immunized, but not from
pepD-immunized mice, to naı¨ve recipients conferred protection
upon challenge. This suggested that antibodies play a role in
protection, an outcome that is consistent with previous demon-
strations that anti-B. burgdorferi antibodies play a significant role in
protection [63–67]. Analysis of pepB-specific antibody isotypes
revealed IgG1 dominance, suggesting a Th2-type immune
response, which was consistent with previous findings [68–70].
Adoptive transfer of splenocytes from pepB-immunized, but not
from pepD-immunized mice, conferred partial protection. This
outcome could have been due, in part, to the presence of pepB-
specific antibodies secreted by memory B-cells in splenocytes. If
the presence of memory B-cells was responsible for the partial
protection, it is not clear why the cells did not undergo recall upon
challenge, but it was notable that no pepB-specific T-cells were
detected in spleens by proliferation assay. In addition, pepB-
specific splenocytes were transferred to recipient mice through
intravenous administration while B. burgdorferi was administered by
subcutaneous needle injection. The discrepancy in administration
of both splenocytes and the infectious agent could explain why the
B-cells injected did not generate enough antibodies to neutralize B.
burgdorferi after infection. Under these circumstances, B-cells will
tend to migrate to the spleen while the borrelial cells will prefer the
draining lymph nodes, skin and joints [4,71,72]. The disparity in
tissue tropisms may account for the discrepancy in the results
observed, where passive transfer of pepB-specific antibodies induce
protection, and the transfer of pepB-specific splenocytes did not
[73]. Additional studies are needed to define the role played by T-
cells in protection.
Further studies need to be done in order to improve the
protection, mostly by improving the delivery method as well as the
hapten/adjuvant with which this antigen is administrated. In
particular, delivery of the vaccine antigen utilizing viral particles
[74,75], as well as the use of microneedles [76–79] for the delivery
of vaccines can significantly improve the immune response and
consequently protection after both needle and tick infection. In
addition, by using transdermal inoculation we will be stimulating
the cell types that most likely will be the encountered by the
bacterium after the tick bite [78,79].
Taken together, an improved DIVA vaccine will significantly
impact the prevention and control of Lyme diseases as well as its
surveillance since it will be compatible with currently available
tests for the detection of Lyme diseases in animals such as IFA,
ELISA and immunoblot assay (in particular, the C6 base
technology (IDEXX laboratories Inc)), without the necessity of
developing further tests to detect infected animals. With the
vaccine antigen pepB, regular ELISA tests can differentiate which
animals have been vaccinated (react to pepB antigen only) from
those that have been infected (react to B. burgdorferi extract only),
and also those that had received the vaccine and are undergoing
infection (react to both pepB and B. burgdorferi extract in ELISA),
making pepB a suitable candidate for the development of a DIVA
vaccine.
Materials and Methods
Ethics statement
All animal experiments were done following the Texas A&M
University IACUC approved animal use protocol #2010-124.
Texas A&M has adopted the ‘‘U.S. Government Principles for the
Utilization and Care of Vertebrate Animals Used in Testing,
Research and Training,’’ and complies with all applicable federal,
state, and local laws which impact the care and use of animals.
Identification of potential vaccine target peptides from
BB0172 antigen
Borrelia burgdorferi strains and growing conditions. B.
burgdorferi B31 A3 (Bb) virulent isolate was used throughout this
study. In order to obtain an antigenic profile similar to that
observed in the natural infection, we grew this bacterium at room
temperature (RT) and pH 7.6 to mimic the unfed tick conditions.
Once the cultures reached a cell density of 1–26107 spirochetes/
ml a subculture was transferred to 37uC, 1% CO2, and pH 6.8
mimicking the conditions in the tick upon feeding. To run the
ELISA tests using whole cell lysates, B. burgdorferi was grown in
500 ml cultures shifted from RT/pH 7.6 to 37uC/pH 6.8 and 1%
CO2. After cultures reached a cell density of 3–5610
7 spirochetes/
ml, cells were harvested, washed three times with HBSS buffer
(HyClone, Thermo Scientific Inc.), quantified, and lysed using
0.1 mm glass beads in 2 ml screw cap tubes in a BeadRuptor 24
(Omni International, Inc). After the lysis cycle, the glass beads
were sedimented by quick centrifugation and the supernatants
were stored at –20uC in 1 ml aliquots until use in the ELISA
assays. For the needle infection experiments, Bb cultures were
similarly prepared. The bacterial cultures were shifted from RT/
pH 7.6 to 37uC/pH 6.8 and reaching a density of 3–56107
spirochetes/ml prior to being harvested, washed three times with
HBSS buffer, and re-suspended in HBSS containing inactivated
normal rabbit serum (50:50, v:v). The cultures were then quantified
and diluted to the appropriate cell density (103 or 105 spirochetes/
ml).
Figure 7. Peptide B-specific antibodies confer protection against B. burgdorferi infection. Antibody titers of control, peptide B-immunized,
and peptide D-immunized animals. Open bars represent the anti-B. burgdorferi titers and black bars represent the peptide-specific antibody titers in
each group (A). Bacterial recuperation from tissues of animals infected after passively transferring peptide specific serum (B) or splenocytes (C) to
naı¨ve mice. Bacterial burden was evaluated by qPCR in skin (D), spleen (E), lymph nodes (F), and joints (G). Bacterial recuperation from tissues and
quantification was done 21 days-post infection. * Denotes statistically significant differences (* P value ,0.05; ** P value , 0.01) when compared
within the passive transfer treatment, while a (P value ,0.05) and b (P value , 0.01) denote significant differences in between animals receiving
serum or splenocytes from the same treatment (peptide B or peptide D).
doi:10.1371/journal.pone.0088245.g007
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Peptide design. The BB0172 antigen is a B. burgdorferi
membrane protein which is poorly immunogenic in the murine
model of Lyme disease [48]. Four peptides within the vWFA
domain of BB0172 were designed considering their probability of
being exposed to the external environment and distance from a
potential internal glycosylation site. The peptides have been
designated by the letters A through D (pepA, pepB, pepC and
pepD). Peptides were synthetized at Peptide 2.0 Inc. (Chantilly,
VA) at 98% purity and conjugated to Keyhole Limpet Hemocy-
anin (KLH) to ensure immunogenicity. The same peptides were
synthetized without conjugation to KLH for in vitro T-cell and
ELISA assays.
Immunization protocol. The protective immunity elicited
by each one of the KLH-conjugated BB0172 peptides (A, B, C or
D), was evaluated in mice. Groups of 6-8 week old female C3H/
HeN mice (n = 12) were inoculated subcutaneously with each one
of the KLH-conjugated peptide at a dose of 50 mg/mouse
formulated in TiterMaxH Gold (v:v, Sigma-Aldrich, St. Louis,
MO) at days 0, 14 and 21 (Fig. 1). A group of six mice similarly
inoculated with adjuvant alone served as the negative controls.
One week after the last boost and prior to challenge, four mice per
group were euthanized and sampled to evaluate the antibody
levels in serum and T-cell proliferation in draining lymph nodes
and spleens. Samples from the heart and tibiotarsal joint from
these mice were evaluated histologically to rule out possible side
effects due to the antigen administration. Mice were infected by
needle inoculation one week after the last boost as described
below.
B. burgdorferi challenge protocols. To determine which
peptide elicited protection in the murine model of Lyme disease,
four mice per immunized group were challenged by subcutaneous
needle inoculation with 103 (low) or 105 (high) Bb/mouse 28 days
post-priming as described above (Fig. 1). The challenge doses used
correspond to 106 and 10006 the infectious dose-50 (ID50),
respectively. Control mice were infected with only one dose, 103
spirochetes/mouse (106 ID50).
To evaluate protection, the mice were euthanized 28 days post-
challenge and blood samples were collected to evaluate antibody
levels. Skin, spleen, inguinal lymph nodes, heart, bladder and
tibiotarsal joint were collected from each mouse for bacterial
recovery in BSK-II media complemented with 6% inactivated
normal rabbit serum and incubated at 32uC and 1% CO2. Five
days post inoculation cultures were blind passed to prevent
inhibition of bacterial growth by tissue degradation. Blind
passaged cultures were incubated at 32uC and 1% CO2 for 15
days before evaluating bacterial growth by dark field microscopy
[49]. One piece of heart and a tibiotarsal joint were collected for
histopathology. Finally, a piece of skin, a small piece of spleen, one
inguinal lymph node and one joint were collected for evaluation of
bacterial burden by qPCR as previously described [50]. All animal
experiments were conducted following the Institutional Animal
Care and Use Committee and the Biosafety committee recom-
mendations.
Histopathology. Mouse tissues were collected 4-weeks post-
priming and 4 weeks after challenge as described above. Tissues
were fixed in 10% buffered formalin, processed for routine
histopathology, paraffin embedded, sectioned and stained with
H&E. The tibiotarsal bones and joints were decalcified in 10%
EDTA prior to being processed for histopathology. A board
certified pathologist blindly evaluated all tissues. Inflammation in
selected tissues were scored from 0–4 based on the following scale:
normal = 0 (no inflammation), minimal = 1 (one small foci of
inflammation), mild = 2 (2–5 foci of inflammation with increased
numbers of inflammatory cells), moderate = 3 (multifocal
inflammation with significant number of inflammatory cells), and
Figure 8. Proliferation assay of T-cells isolated from lymph
nodes and spleens of mice immunized with peptide B (grey
bars), peptide D (open bars) and controls (closed bars). (A)
Proliferation assay at 8 weeks post-priming. Notice the high activity of
cells isolated from lymph nodes of immunized compared with the
control mice without any stimulation of the cultures. Proliferation assay
of cell isolated from lymph nodes (B) and spleens (C) at 12 weeks post-
priming. Concavalin A (ConA) was used as positive control for
stimulation of the cell cultures. Specific peptides and B. burgdorferi
B31 A3 strain whole cell lysates were used as test antigens to stimulate
the cultures. Mean 6 standard error of the mean, is represented for
each lymphocyte proliferation measured. * Denotes statistically
significant differences (* P value ,0.05; ** P value , 0.01) when
compared with the control group.
doi:10.1371/journal.pone.0088245.g008
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severe = 4 (multifocal to diffuse, with more than 30% of section
infiltrated with inflammatory cells) [51].
Enzyme linked Immuno-sorbent Assay. Sera from
immunized mice (0, and 4 weeks post-priming) as well as from
animals immunized and then challenged (4 weeks post-challenge)
were evaluated for IgG and IgM levels by ELISA. 96-well
MaxiSorbH plates (Nunc, Thermo Scientific, Ltd.) were coated
overnight at 4uC with either 500 ng/well of each one of the
BB0172 peptides or with the whole cell lysate of B. burgdorferi A3
strain (107 Borrelia/well) grown at RT/pH7.6 and shifted to
37uC/pH 6.8 as described above. Carbonate buffer pH 9.1 was
used for coating the ELISA plates and after coating, the plates
were washed three times in Phosphate Buffered Saline (PBS)
containing 0.2% Tween 20 (PBS-T) and blocked for 2 hours at
room temperature in PBS-T containing 3% Bovine Serum
Albumin (BSA). Blocked plates were washed three times in PBS-
T and mouse serum samples were added in duplicates and in 2-
fold serial dilutions ranging from 1:100 to 1:102,400 in PBS-T
containing 1% BSA. Plates were incubated for 1 hour at room
temperature and unbound primary antibodies were removed by
washing plates three times in PBS-T. Secondary anti-mouse HRP
conjugated antibody was added to the plates at 1:3000 dilution in
PBS-T containing 1% BSA. After washing, plates were incubated
with OPD (o-phenylenediamine dihydrochloride) color substrate
following manufacturer recommendations (Pierce, Thermo Scien-
tific, Ltd). After a 20-minute incubation in the dark, plates were
read at a wavelength of 450 nm and analyzed using the BMI
LABTECH OMEGA plate reader and software. All samples were
evaluated in triplicates.
Efficacy of pepB vaccine
B. burgdorferi growing conditions. Bb B31 A3 virulent
isolate was also used throughout this section of the study. Culture
conditions were the same as described above. In addition, Bb used
for in vitro infection of Ixodes scapularis nymphs was grown in BSK-II
media pH 7.6 and 1% CO2 until cultures reached a cell density of
26107 spirochetes/ml.
Immunization protocol. The same immunization protocol
as described in the target identification phase above was used in
the efficacy study (Fig. 4A). PepB was used to immunized mice
(n = 12) since it was the only peptide that conferred protection in
the target identification phase. PepD (n = 12) served as an internal
negative control since it did not confer protection and in addition,
a control group receiving adjuvant only was also included (n = 12).
Vaccine safety was evaluated at 8 and 12 weeks post-priming (Fig.
4A). Protection was evaluated 12-weeks post-priming following
challenge using Bb-infected ticks (Fig. 4A). Four-weeks post-
challenge, the mice were euthanized and protection and safety
were evaluated as described below.
Passive transfer protocol. To evaluate the role of antibodies
and lymphocytes in the protection induced against Lyme disease in
mice immunized with pepB, we conducted passive transfer studies
in which groups of donor mice (control, pepB and pepD) were
immunized following the immunization protocol described above
(Fig. 4B). Twelve weeks post-priming, the mice were euthanized,
and blood and spleens were collected. Splenocytes were isolated
from each of the groups as well as serum following procedures
described elsewhere [52], and pooled splenocytes and serum were
passively transferred to recipient mice (Fig. 4B). Recipient mice
were divided into 6 groups (n = 10). Three groups were inoculated
with 300 ml/mouse of serum samples from control, pepB or pepD-
immunized mice, whereas the other three groups were similarly
inoculated but with 46107splenocytes/mouse from control,
pepB, or pepD-immunized mice, respectively. Forty-eight hours
post-transfer, all the mice were challenged by needle inoculation
with either a low or a high dose of B. burgdorferi as described below.
Four weeks post-infection, the mice were euthanized and protection
evaluated (Fig. 4B).
B. burgdorferi challenge protocols. The protection elicited
by the peptides B and D in the murine model of Lyme disease was
evaluated by challenging the mice with infected I. scapularis ticks
(Fig. 4A) 12-weeks post-priming. To conduct this study, naı¨ve I.
scapularis nymphs were purchased from the Oklahoma State
University Tick Laboratory. Nymphs were desiccated for 4 days at
79% relative humidity (RH) in a chamber, then were dipped in a
suspension of 108 spirochetes/ml for 45 minutes. After the 45
minute infection, the ticks were washed and placed in the same
79% RH chamber for 3 days in order to improve attachment of
the nymphs to mice [53]. Prior to the challenge, a group of 10 ticks
was used to evaluate the level of infection with B. burgdorferi by
quantitative real time PCR (qPCR). Immunized C3H/HeN mice
were infested with 5 infected nymphs per mouse and housed in
wire bottom cages following standard operational procedures.
Ticks were left to feed on mice until repletion.
The challenge protocol described in the target identification
phase was used to evaluate the protection conferred by passive
transfer of specific serum or adoptive transfer of splenocytes (Fig.
4B). In both needle and tick challenge, mice were euthanized 28
days post-infection and blood samples were collected to evaluate
antibody levels. Skin, spleen, inguinal lymph nodes, heart, bladder
and tibiotarsal joint were collected from each mouse for bacterial
recovery in BSK-II media as previously described [49]. One ear, a
piece of liver, one kidney, a piece of heart and a tibiotarsal joint
were collected for histopathology. Finally, a piece of skin, a small
piece of spleen, one inguinal lymph node and one joint were
collected for evaluation of bacterial burden by qPCR as previously
described [50].
Enzyme linked Immuno-sorbent Assay. Sera from
immunized mice (0, 4, 8, and 12 weeks post-priming) as well as
from animals immunized and then challenged (4 weeks post-
challenge) were evaluated for IgG and IgM levels by ELISA as
described above.
Histopathology. Mouse tissues were collected after immuni-
zation (4, 8, and 12 weeks post-priming) and 4 weeks after
challenge as described above. Tissues were processed in the same
way as described in the target identification phase above. A board
certified pathologist blindly evaluated all tissues, and inflammation
in selected tissues was scored from 0–4 as described above.
T-cell proliferation assay. Priming of Bb pepB-specific T-
cell responses was tested by proliferation assays using cells isolated
from the lymph nodes or spleens as previously described [54,55].
Two months post-immunization, single cell suspensions were
isolated from pooled lymph nodes or spleens from four mice
immunized with the KLH-pepB conjugate or from three control
mice. Proliferation assay was conducted using 56105 cells/well in
triplicate-wells of 96-well plates in a total volume of 100 ml of
complete medium containing different doses of pepB (0.01, 0.1, 1,
2.5, 5, or 10 mg/ml). The positive control was 1.25 mg/ml
concanavalin A (conA), whereas medium alone served as a
negative control. In addition, whole cell lysates of B. burgdorferi B31
A3 isolate was included in this assay (serial dilutions as above). The
cells were cultured for 72 hours at 37uC with 5% CO2 then
labeled with 0.25 mCi of 3H-thymidine for 6 hours, collected using
an automated cell harvester (Tomtec). The incorporated 3H-
thymidine was counted with a liquid scintillation counter. The
incorporation of 3H-thymidine by the proliferating lymphocytes
was presented as mean counts per minute (cpm) of triplicate wells.
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In a second experiment, cells were isolated from the lymph
nodes and spleens from mice 3 months post-immunization with
the KLH-pepB conjugate and proliferations assays were conduct-
ed as above. Naı¨ve mice and mice immunized with KLH-pepD
conjugate served as controls. The positive control was 1.25 mg/ml
conA, whereas medium alone served as a negative control. In
addition, whole cell lysates of B. burgdorferi B31 A3 isolate was also
included in this assay. The cultures were labeled and processed as
above.
Statistics
Bacterial recovery from tissues was analyzed using the Two-way
ANOVA to determine significant differences in between treat-
ments. Quantitative real time PCR data were analyzed using the
Mann Whitney U test to determine differences in the bacterial
burden determined in each group compared with the control
group. In addition, antibody levels were also analyzed utilizing a
Two-way ANOVA with the Bonferroni multiple comparison test,
in which all groups were compared to the control group. All tests
and graphics were performed using Prism 6.0d (GraphPad
Software, Inc.).
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